{
    "title": "Pfizer considers cost cuts as demand for COVID products falls",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12360995/Pfizer-considers-cost-cuts-demand-COVID-products-wanes.html",
    "date": "2023-08-01",
    "keywords": [
        "vaccine",
        "pfizer",
        "company",
        "revenue",
        "bhanvi",
        "satija",
        "michael",
        "covid19",
        "treatment",
        "covid",
        "market",
        "year",
        "infection",
        "bourla",
        "vaccination",
        "rsv",
        "cost",
        "quarter",
        "tuesday",
        "program",
        "demand",
        "clarity",
        "size",
        "autumn",
        "government",
        "chief",
        "executive",
        "albert",
        "predictor",
        "upside",
        "flu",
        "virus",
        "combination",
        "part",
        "plan",
        "midday",
        "trading",
        "inc",
        "novavax",
        "comirnaty",
        "partner",
        "biontech",
        "paxlovid",
        "business",
        "end",
        "drugmaker",
        "damage",
        "warehouse",
        "mount",
        "facility",
        "recommendation",
        "concern",
        "cancer",
        "drug",
        "talzenna",
        "patient",
        "population",
        "patent",
        "protection",
        "deal",
        "cancertherapy",
        "specialist",
        "seagen",
        "product",
        "portfolio",
        "profit",
        "share",
        "street",
        "bengaluru",
        "erman",
        "york",
        "editing",
        "kalluvila",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}